Revolution Medicines (RVMD) Total Liabilities (2018 - 2026)

Revolution Medicines has reported Total Liabilities for 9 years, with the latest figure at $753.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 162.47% year-over-year to $753.8 million; the trailing twelve-month figure through Mar 2026 stood at $753.8 million (up 162.47% YoY), and the FY2025 full-year result was $723.2 million, up 146.75% from the prior year.
• Total Liabilities for Q1 2026 stood at $753.8 million, up from $723.2 million in the prior quarter.
• The five-year high for Total Liabilities was $753.8 million in Q1 2026, with the low at $121.0 million in Q1 2023.
• Average Total Liabilities over 5 years is $295.8 million, with a median of $189.6 million recorded in 2024.
• Year-over-year, Total Liabilities declined 8.16% in 2023 and surged 233.01% in 2025.
• Tracing RVMD's Total Liabilities over 5 years: stood at $126.7 million in 2022, then surged by 85.82% to $235.5 million in 2023, then advanced by 24.45% to $293.1 million in 2024, then surged by 146.75% to $723.2 million in 2025, then grew by 4.23% to $753.8 million in 2026.
• The last three Total Liabilities figures came in at $753.8 million (Q1 2026), $723.2 million (Q4 2025), and $655.0 million (Q3 2025), per Business Quant data.

Peer Comparison